发文地区与机构
近年国家 / 地区发文量统计
| 国家 / 地区 | 发文量 |
|---|---|
| USA | 498 |
| Canada | 110 |
| England | 92 |
| GERMANY (FED REP GER) | 74 |
| Netherlands | 69 |
| France | 56 |
| Italy | 55 |
| Australia | 52 |
| Sweden | 48 |
| Switzerland | 48 |
近年机构发文量统计
| 机构 | 发文量 |
|---|---|
| DUKE UNIVERSITY | 193 |
| HARVARD UNIVERSITY | 111 |
| STANFORD UNIVERSITY | 56 |
| BRIGHAM & WOMEN'S HOSPITAL | 53 |
| UNIVERSITY OF CALIFORNIA SYSTEM | 51 |
| MAYO CLINIC | 50 |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 43 |
| COLUMBIA UNIVERSITY | 40 |
| US DEPARTMENT OF VETERANS AFFAIRS | 39 |
| JOHNS HOPKINS UNIVERSITY | 35 |
文章引用情况
1
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial2
Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial3
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?4
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry5
A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs6
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF7
Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF)8
Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults9
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial10
Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD)